The $122.5M upfront provides near-term cash runway extension without dilution, but the sale of manufacturing capabilities signals a shift to a more asset-light model. Monitor Q3 2026 closing and any pipeline updates (e.g., lorigerlimab data) that could drive re-rating. Historical performance on MGNX shows poor follow-through on bullish calls — be cautious on upside.
Price Chart
Executive Summary
MacroGenics is selling its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfront payment. The deal transfers the Rockville, MD facility (11,000L capacity), Frederick warehouse, and ~140 employees to Bora, while MacroGenics retains a supply arrangement for its pipeline needs. This non-dilutive capital infusion supports the company's pipeline advancement but reflects a strategic pivot away from internal manufacturing.
Key Financial Metrics
Key Facts
- Upfront payment of $122.5 million from Bora Pharmaceuticals upon closing.
- Transfer of Rockville, MD manufacturing site (11,000L capacity) and Frederick, MD warehouse.
- Approximately 140 MacroGenics employees expected to be hired by Bora.
- MacroGenics will have a supply arrangement with Bora for process development and drug substance production.
- Transaction expected to close in Q3 2026.
- Moelis & Company and Sidley Austin advised MacroGenics; Jones Day advised Bora.
Financial Impact
$122.5 million upfront payment, non-dilutive capital for pipeline funding.
Risk Factors
- Closing conditions may delay or prevent transaction completion.
- Loss of internal manufacturing control could increase dependency on Bora for supply.
- Pipeline setbacks (e.g., clinical trial failures) could erode the value of the capital infusion.
- Historical T+20 performance on MGNX bullish calls is poor (25% win rate, avg -0.51% T+20).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 8, 2026 12w ago | 8-K | $4.57 $4.01 | ▼ −12.25% | ▼ −14.50% | $3.58 (−21.66%) |
Jul 2, 2026 13w ago | Press Release | $4.71 $3.78 | ▼ −19.75% | ▼ −19.33% | $3.58 (−23.99%) |
Jun 12, 2026 16w ago | Institutional Cluster | $3.96 $4.33 | ▲ +9.34% | ▲ +7.56% | $3.58 (−9.60%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.01 $4.57 | ▲ +13.97% | ▲ +12.07% | $3.58 (−10.72%) |
May 13, 2026 20w ago | 8-K | $4.16 $3.96 | ▼ −4.81% | ▼ −3.95% | $3.58 (−13.94%) |
May 12, 2026 20w ago | 8-K | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
May 11, 2026 20w ago | Press Release | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
Apr 8, 2026 25w ago | 8-K | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | Press Release | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | DEFA14A | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access